Minerva Neurosciences to Report First Quarter 2017 Financial Results and Business Updates on May 4, 2017
April 27 2017 - 8:30AM
Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage
biopharmaceutical company focused on the development of therapies
to treat central nervous system (CNS) disorders, today announced
that it will release financial results and business updates for the
first quarter of 2017 on Thursday, May 4, 2017. The Company
will host a webcast and conference call that day at 8:30 a.m.
Eastern Time to discuss these results and updates.
The live call may be accessed by dialing (877) 312-5845 for
domestic callers or (765) 507-2618 for international callers and
referring to conference ID number 2971783. A live webcast of
the conference call will be available online in the Investors and
Media section of the Company’s website at
ir.minervaneurosciences.com. The archived webcast will be
available on the Company’s website beginning approximately two
hours after the event for 30 days.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of a portfolio of product candidates to treat CNS
diseases. Minerva’s proprietary compounds include: MIN-101,
in clinical development for schizophrenia; MIN-117, in clinical
development for major depressive disorder (MDD); MIN-202
(JNJ-42847922), in clinical development for insomnia and MDD; and
MIN-301, in pre-clinical development for Parkinson’s disease.
Minerva’s common stock is listed on the NASDAQ Global Market under
the symbol “NERV.” For more information, please visit
www.minervaneurosciences.com.
Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Apr 2023 to Apr 2024